{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-002368","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2026-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.786952+00:00","generated_at":"2026-05-16T11:40:32.322592+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Crinetics PALSONIFY Q4 net revenue >$5M; atumelnant Phase 2 CAH shows 67% A4 reduction","bullets":["Unaudited Q4 2025 PALSONIFY net product revenue exceeded $5.0M, with >200 enrollment forms and >125 unique prescribers.","Atumelnant 80mg in CAH cohort 4: 67% mean reduction in androstenedione, 88% of patients achieved physiologic glucocorticoid doses.","No serious adverse events or hepatic transaminase AEs in cohort 4 or open-label extension (25 patients, >750 weeks cumulative exposure).","About half of new PALSONIFY bottles reimbursed without Quickstart bridge; 12-month prior authorizations typical.","Crinetics hosts investor call today 8:30 AM ET to discuss results and outlook."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-002368","json":"https://secwatch.observer/filing/0001193125-26-002368.json","markdown":"https://secwatch.observer/filing/0001193125-26-002368.md","text":"https://secwatch.observer/filing/0001193125-26-002368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000119312526002368/0001193125-26-002368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000119312526002368/d86003d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:40:32.322592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}